Marcus Smith Noel, MD SM-88, a novel oral compound that is making headway in various solid tumors, has shown early efficacy in patients with metastatic pancreatic cancer. If the regimen continues to be well tolerated, according to Marcus Smith Noel, MD, it may have a place in the third-line setting, which is currently an area of significant unmet need.
The drug, which works by attacking oncogenic metabolism, is comprised of 4 oral agents: a tyrosine derivative (D,L-alpha-metyrosine), an mTOR inhibitor (sirolimus), a CYP3a4 inducer (phenytoin), and an oxidative stress catalyst (methoxsalen). Read more . . .